LFA
HAE icon

Legacy Financial Advisors’s Haemonetics HAE Stock Holding History

Legacy Financial Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-56
Closed -$5K – 436
2019
Q1 		$5K Buy
+56
New +$5.09K ﹤0.01% 770

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Legacy Financial Advisors's HAE Position: Q2 2019 in Review

Legacy Financial Advisors sold out of Haemonetics (HAE) in Q2 2019, closing a stake of 56 shares — an estimated $5K sold.

Legacy Financial Advisors first reported a position in HAE in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 256 funds tracked by Wall St. Rank hold HAE as of Q2 2019.

  • Legacy Financial Advisors reported no remaining Haemonetics position as of Q2 2019 after selling out during the quarter.
  • Legacy Financial Advisors sold 56 Haemonetics shares in Q2 2019, an estimated $5K.
  • Legacy Financial Advisors first reported a position in Haemonetics in Q1 2019 and held it in 1 quarter.
  • Legacy Financial Advisors's Haemonetics position peaked at $5K in Q1 2019.
  • 256 funds tracked by Wall St. Rank held Haemonetics as of Q2 2019.

Based on Legacy Financial Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.